Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Lisa Bero to Health Policy

This is a "connection" page, showing publications Lisa Bero has written about Health Policy.

 
Connection Strength
 
 
 
4.928
 
  1. Chiu K, Thow AM, Bero L. Understanding the Dynamics of More Restrictive Medicines Policy: A Case Study of Codeine Up-Scheduling in Australia. Int J Health Policy Manag. 2023; 12:6872.
    View in: PubMed
    Score: 0.649
  2. Parker L, Fabbri A, Grundy Q, Mintzes B, Bero L. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ. 2019 12 12; 367:l6694.
    View in: PubMed
    Score: 0.526
  3. Wang Z, Grundy Q, Parker L, Bero L. Health promoter, advocate, legitimiser - the many roles of WHO guidelines: a qualitative study. Health Res Policy Syst. 2019 Dec 05; 17(1):96.
    View in: PubMed
    Score: 0.525
  4. Apollonio DE, Bero LA. Interpretation and use of evidence in state policymaking: a qualitative analysis. BMJ Open. 2017 02 20; 7(2):e012738.
    View in: PubMed
    Score: 0.433
  5. Bero L. Systematic Review: A Method at Risk for Being Corrupted. Am J Public Health. 2017 Jan; 107(1):93-96.
    View in: PubMed
    Score: 0.425
  6. Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med. 2013 Mar 11; 173(5):338-43.
    View in: PubMed
    Score: 0.329
  7. Cook DM, Bero LA. The politics of smoking in federal buildings: an executive order case study. Am J Public Health. 2009 Sep; 99(9):1588-95.
    View in: PubMed
    Score: 0.256
  8. Jewell CJ, Bero LA. "Developing good taste in evidence": facilitators of and hindrances to evidence-informed health policymaking in state government. Milbank Q. 2008 Jun; 86(2):177-208.
    View in: PubMed
    Score: 0.237
  9. Cook DM, Tong EK, Glantz SA, Bero LA. The power of paperwork: how Philip Morris neutralized the medical code for secondhand smoke. Health Aff (Millwood). 2005 Jul-Aug; 24(4):994-1004.
    View in: PubMed
    Score: 0.193
  10. White J, Bero LA. Public health under attack: the American Stop Smoking Intervention Study (ASSIST) and the tobacco industry. Am J Public Health. 2004 Feb; 94(2):240-50.
    View in: PubMed
    Score: 0.175
  11. Joosse IR, Tordrup D, Bero L, Mantel-Teeuwisse AK, van den Ham HA. A critical review of methodologies used in pharmaceutical pricing policy analyses. Health Policy. 2023 Aug; 134:104576.
    View in: PubMed
    Score: 0.154
  12. Wang Z, Grundy Q, Parker L, Bero L. Variations in processes for guideline adaptation: a qualitative study of World Health Organization staff experiences in implementing guidelines. BMC Public Health. 2020 Nov 23; 20(1):1758.
    View in: PubMed
    Score: 0.140
  13. Soares-Weiser K, Lasserson T, Jorgensen KJ, Woloshin S, Bero L, Brown MD, Fischhoff B. Policy makers must act on incomplete evidence in responding to COVID-19. Cochrane Database Syst Rev. 2020 11 20; 11:ED000149.
    View in: PubMed
    Score: 0.140
  14. Mialon M, Vandevijvere S, Carriedo-Lutzenkirchen A, Bero L, Gomes F, Petticrew M, McKee M, Stuckler D, Sacks G. Mechanisms for addressing and managing the influence of corporations on public health policy, research and practice: a scoping review. BMJ Open. 2020 07 19; 10(7):e034082.
    View in: PubMed
    Score: 0.137
  15. Bero LA, Jadad AR. How consumers and policymakers can use systematic reviews for decision making. Ann Intern Med. 1997 Jul 01; 127(1):37-42.
    View in: PubMed
    Score: 0.111
  16. Bero LA, Glantz SA, Rennie D. Publication bias and public health policy on environmental tobacco smoke. JAMA. 1994 Jul 13; 272(2):133-6.
    View in: PubMed
    Score: 0.090
  17. Apollonio DE, Glantz SA, Bero LA. Term limits and the tobacco industry. Soc Sci Med. 2014 Mar; 104:1-5.
    View in: PubMed
    Score: 0.086
  18. Apollonio DE, Bero LA. Evidence and argument in policymaking: development of workplace smoking legislation. BMC Public Health. 2009 Jun 17; 9:189.
    View in: PubMed
    Score: 0.064
  19. Odierna DH, Bero LA. Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations. J Clin Epidemiol. 2009 Dec; 62(12):1268-78.
    View in: PubMed
    Score: 0.063
  20. Kummerfeldt CE, Barnoya J, Bero L. Philip Morris involvement in the development of an air quality laboratory in El Salvador. Tob Control. 2009 Jun; 18(3):241-4.
    View in: PubMed
    Score: 0.062
  21. Cook DM, Gurugubelli RK, Bero LA. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings. Drug Saf. 2009; 32(11):1057-66.
    View in: PubMed
    Score: 0.062
  22. Schotland MS, Bero LA. Evaluating public commentary and scientific evidence submitted in the development of a risk assessment. Risk Anal. 2002 Feb; 22(1):131-40.
    View in: PubMed
    Score: 0.038
  23. Phillips KA, Bero LA. Improving the use of information in medical effectiveness research. Int J Qual Health Care. 1996 Feb; 8(1):21-30.
    View in: PubMed
    Score: 0.025
  24. Granados A, Jonsson E, Banta HD, Bero L, Bonair A, Cochet C, Freemantle N, Grilli R, Grimshaw J, Harvey E, Levi R, Marshall D, Oxman A, Pasart L, R?is?nen V, Rius E, Espinas JA. EUR-ASSESS Project Subgroup Report on Dissemination and Impact. Int J Technol Assess Health Care. 1997; 13(2):220-86.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)